STOCK TITAN

BridgeBio Pharma, Inc. - BBIO STOCK NEWS

Welcome to our dedicated page for BridgeBio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma stock.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.

The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.

BridgeBio’s robust pipeline boasts several notable programs:

  • Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
  • Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
  • BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.

BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.

Key recent developments include:

  • The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
  • Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
  • Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.

BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.

Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) has announced a partnership with UC San Diego to translate research in genetically driven conditions into therapeutic applications, focused on oncology and neurology. The collaboration aims to identify promising research programs and potentially sponsor them for clinical investigation. This partnership is part of BridgeBio's commitment to develop life-changing medicines for patients, utilizing its developmental expertise alongside UC San Diego's research capabilities. BridgeBio currently has 20 partnerships with leading academic institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) has announced a partnership with UC Davis to enhance research and development for genetic diseases and cancers. The collaboration aims to explore and assess potential research projects in genetic disorders and precision oncology. BridgeBio emphasizes its commitment to translating innovative research into effective treatments, leveraging its partnerships with various academic institutions. This alliance marks a strategic move to expand BridgeBio’s initiatives in developing therapies for genetically driven conditions, enhancing its portfolio of over 30 development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with Roswell Park Comprehensive Cancer Center to develop investigational therapies for genetically driven cancers. This partnership marks a significant step in BridgeBio's efforts to advance cancer treatment, allowing for new research opportunities and accelerated clinical pathways. The collaboration is part of BridgeBio's broader strategy to engage with leading academic institutions to translate scientific discoveries into effective treatments efficiently.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) announced a collaboration with Oregon Health & Science University (OHSU) to develop investigational therapies for genetically driven conditions. This partnership extends five years of informal collaboration and aims to leverage OHSU's research capabilities to advance potential treatments for diseases like cancer. The collaboration underscores BridgeBio's commitment to rapidly translating genetic research into clinical applications, enhancing its portfolio of over 30 development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with The Lundquist Institute to develop treatments for genetically driven diseases and cancers. This two-year partnership aims to harness Lundquist's research capabilities and BridgeBio's resources to identify potential therapies. The partnership extends BridgeBio's network to 20 academic and research institutions, emphasizing their commitment to pioneering medicines for patients. CEO Neil Kumar expressed optimism about translating scientific discoveries into meaningful treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
-
Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with the Canadian Glycomics Network (GlycoNet) aimed at translating glycomics research into treatments for genetic diseases. The partnership intends to foster research programs and clinical investigations, leveraging glycomics insights for therapeutic advancements. BridgeBio has previously partnered with various academic institutions, enhancing its research capabilities. This collaboration is expected to streamline the development of treatments for genetic disorders, addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
Rhea-AI Summary

BridgeBio Pharma (NASDAQ: BBIO) has partnered with Brown University to enhance research in genetically driven neurological disorders. The collaboration aims to advance treatment methods for complex brain diseases, leveraging Brown's neurology expertise. Under this partnership, promising discoveries will be evaluated, with opportunities for Brown scientists to take leadership roles in developing therapeutic programs. This collaboration is part of BridgeBio's strategy to translate genetic research into viable medicines, complementing its existing 20 partnerships with leading academic institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
partnership
-
Rhea-AI Summary

BridgeBio Pharma granted restricted stock units totaling 32,691 shares to 19 new employees, as part of its 2019 Inducement Equity Plan. The awards were announced on April 5, 2021, following Nasdaq Listing Rule 5635(c)(4), which requires such grants as inducements for employees entering the company. BridgeBio focuses on developing transformative medications for genetic diseases and cancers, with a pipeline of over 30 development programs from early science to advanced clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
none
-
Rhea-AI Summary

BridgeBio and Helsinn have entered a global collaboration to co-commercialize infigratinib for oncology, sharing profits equally. Helsinn will exclusively develop and commercialize infigratinib outside the U.S., excluding China and nearby regions. BridgeBio stands to gain over $2 billion in milestone payments. The FDA has granted Priority Review for infigratinib for cholangiocarcinoma, highlighting its potential in treating FGFR-driven cancers. This partnership aims to accelerate the launch and broaden research into infigratinib's applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
none
Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced promising early results from a Phase 2b study of encaleret for treating Autosomal Dominant Hypocalcemia Type 1 (ADH1). Out of six participants, 100% showed normalization of blood and urine calcium levels within five days. Encaleret was reported to be well-tolerated with no serious adverse events, suggesting significant efficacy potential. The company plans to discuss regulatory pathways in 2021 to potentially become the first approved therapy for ADH1. A webcast to discuss these results is scheduled for March 22, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of BridgeBio Pharma (BBIO)?

The current stock price of BridgeBio Pharma (BBIO) is $28.12 as of January 3, 2025.

What is the market cap of BridgeBio Pharma (BBIO)?

The market cap of BridgeBio Pharma (BBIO) is approximately 5.4B.

What does BridgeBio Pharma, Inc. specialize in?

BridgeBio Pharma specializes in discovering, creating, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers.

What are the core focus areas of BridgeBio Pharma's pipeline?

The core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy.

What are some key programs in BridgeBio's pipeline?

Key programs include acoramidis (AG10) for ATTR-CM, infigratinib for achondroplasia and hypochondroplasia, and BBP-418 for LGMD2I/R9.

What recent financial achievements has BridgeBio Pharma accomplished?

BridgeBio recently completed a $200 million private financing for its oncology subsidiary and has conducted multiple public offerings.

Has BridgeBio Pharma formed any significant partnerships?

Yes, BridgeBio has partnered with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets.

What recent clinical trial results has BridgeBio Pharma announced?

BridgeBio announced positive results from the Phase 3 ATTRibute-CM trial for acoramidis, showing significant improvements in health-related quality of life for patients with ATTR-CM.

When was BridgeBio Pharma founded?

BridgeBio Pharma was founded in 2015.

Where is BridgeBio Pharma headquartered?

BridgeBio Pharma is headquartered in Palo Alto, California.

What is the therapeutic approach of BridgeBio Pharma?

BridgeBio Pharma applies a systematic mapping of the genetic disease landscape to identify promising therapeutic assets and leverages its proprietary platform to develop these assets into impactful treatments.

How can I learn more about BridgeBio Pharma’s developments?

For more information, visit bridgebio.com and follow BridgeBio on LinkedIn and Twitter.
BridgeBio Pharma, Inc.

Nasdaq:BBIO

BBIO Rankings

BBIO Stock Data

5.37B
154.31M
5.42%
94.14%
8.99%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PALO ALTO